Helicobacter pylori (H. pylori) is a spiral-shaped bacterium that lives in the lining of the stomach and, in some cases, the upper small intestine. It is one of the most common bacteria found in humans worldwide. While many people carry H. pylori without symptoms, in some individuals it can cause inflammation of the stomach lining (gastritis), ulcers, and, over time, digestive discomfort or nutrient absorption issues. H. pylori is typically acquired during childhood and can persist throughout life if untreated. It spreads mainly through saliva, food, or water contaminated with the bacteria.

The marker Helicobacter pylori Abs, Serum, detected through a serology test using the immunochromatography method, is a crucial diagnostic tool in identifying infections caused by the Helicobacter pylori bacteria. This bacteria is known to cause various gastrointestinal issues, including peptic ulcers and chronic gastritis, and is also associated with an increased risk of stomach cancer. The test works by detecting specific antibodies in the blood that are produced in response to an H. pylori infection. The immunochromatography method is a simple and rapid technique that involves a test strip, which, when exposed to a blood sample, will show visible lines indicating the presence or absence of these antibodies. The process is straightforward and non-invasive, making it a convenient option for both patients and healthcare providers. A positive result indicates that the individual has been exposed to the bacteria and has developed an immune response, while a negative result suggests the absence of an active infection. This test is particularly useful for initial screenings and for confirming suspicions of H. pylori-related gastrointestinal conditions, guiding further diagnostic and treatment decisions. ----------------- Helicobacter pylori Abs, Serum: Understanding a Positive Test Result A positive test result for Helicobacter pylori Abs, Serum indicates that the individual has been exposed to the Helicobacter pylori bacteria and their immune system has produced antibodies in response. This typically means there is or has been an infection with H. pylori, which may require further medical evaluation and treatment. Conditions Associated with Elevations Elevated levels of Helicobacter pylori antibodies in the serum are associated with: Peptic Ulcer Disease: H. pylori is a major cause of peptic ulcers, which are sores that develop on the lining of the stomach, small intestine, or esophagus. Chronic Gastritis: Long-term infection can lead to chronic inflammation of the stomach lining. Gastric MALT Lymphoma: This type of stomach cancer is linked to chronic H. pylori infection. Gastric Cancer: Persistent infection with H. pylori increases the risk of developing gastric adenocarcinoma. Treatment Considerations If a patient tests positive for H. pylori antibodies, the following treatment options are typically considered: Antibiotic Therapy: A combination of antibiotics, such as clarithromycin, amoxicillin, or metronidazole, is often prescribed to eradicate the bacteria. Proton Pump Inhibitors (PPIs): These medications, like omeprazole, reduce stomach acid, helping to heal the stomach lining. Bismuth Subsalicylate: Sometimes included in treatment regimens to protect the stomach lining and improve antibiotic effectiveness. Follow-Up Testing: After completing treatment, follow-up tests such as the urea breath test, stool antigen test, or endoscopy may be recommended to confirm eradication of the bacteria. Correlated Panels Other biomarker panels that may be correlated with H. pylori infection include: Urea Breath Test: Measures isotopic carbon dioxide in the breath after ingestion of a urea solution. Stool Antigen Test: Detects H. pylori antigens in a stool sample. Gastric Biopsy: Obtained via endoscopy to directly visualize and test stomach tissue for H. pylori. Nutrient Associations H. pylori infection can impact nutrient absorption, leading to deficiencies such as: Iron: Chronic gastritis can cause decreased iron absorption, leading to anemia. Vitamin B12: H. pylori can interfere with the stomach’s ability to absorb vitamin B12, potentially leading to deficiency and associated symptoms like fatigue and neurological issues. Vitamin C: The bacteria can reduce the stomach’s acid environment, affecting vitamin C absorption. References Marshall, B. J., & Warren, J. R. (1984). Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. The Lancet, 323(8390), 1311-1315. Suerbaum, S., & Michetti, P. (2002). Helicobacter pylori infection. New England Journal of Medicine, 347(15), 1175-1186. Malfertheiner, P., et al. (2012). Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report. Gut, 61(5), 646-664. Testerman, T. L., & Morris, J. (2014). Beyond the stomach: an updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. World Journal of Gastroenterology: WJG, 20(36), 12781.

Part of Stool

The Helicobacter Pylori Ag, EIA, STOOL test by Quest Diagnostics is a diagnostic tool used to detect the presence of Helicobacter pylori (H. pylori) antigens in a stool sample. H. pylori is a type of bacteria that infects the stomach lining and is a leading cause of peptic ulcers, chronic gastritis, and has been associated with stomach cancer. Detecting and treating H. pylori infections early can prevent these severe gastrointestinal conditions. This test works by identifying specific antigens, which are proteins produced by the H. pylori bacteria, in the patient's stool. A stool sample is collected and sent to Quest Diagnostics for analysis using an enzyme immunoassay (EIA). This method is highly sensitive and specific, making it an effective way to diagnose an active H. pylori infection. The non-invasive nature of the test, which only requires a stool sample, makes it suitable for all age groups, including children and the elderly. Results from the Helicobacter Pylori Ag, EIA, STOOL test provide clear information about the presence of an H. pylori infection. A positive result indicates that H. pylori antigens are present in the stool, suggesting an active infection. In this case, healthcare providers typically recommend a treatment regimen that includes antibiotics to eradicate the bacteria and medications to reduce stomach acid, which helps in healing the stomach lining. It is crucial to follow the entire prescribed treatment to ensure the infection is fully cleared and to prevent recurrence. A negative result indicates that no H. pylori antigens were detected in the stool sample, suggesting there is no current infection. However, if symptoms of H. pylori infection, such as persistent stomach pain, nausea, frequent burping, or unexplained weight loss, persist, further diagnostic testing may be necessary to identify other potential causes of these symptoms. The Helicobacter Pylori Ag, EIA, STOOL test does not require any special preparation, but patients should inform their healthcare provider about any medications they are taking, as certain drugs, like antibiotics and proton pump inhibitors, can affect the test results. If the test results are positive, a follow-up test may be conducted several weeks after completing treatment to ensure the infection has been successfully eradicated. Understanding and interpreting the results of the Helicobacter Pylori Ag, EIA, STOOL test is essential for effective management and treatment of H. pylori infections. Early detection through this reliable and non-invasive test can lead to timely treatment, preventing more serious gastrointestinal diseases and promoting better overall health.

Part of Blood Health

Hemoglobin A, featured prominently on the Thalassemia and Hemoglobinopathy Comprehensive (COMP) panel, is a critical component in diagnosing and managing blood disorders. This panel is an essential tool used to detect various forms of thalassemia and hemoglobinopathies, conditions characterized by abnormal hemoglobin production. Hemoglobin A, the most common form of hemoglobin in adults, is composed of two alpha and two beta globin chains. The Thalassemia and Hemoglobinopathy COMP panel measures the percentage of Hemoglobin A in the blood, which is crucial for diagnosing conditions like beta-thalassemia or sickle cell disease. In normal individuals, Hemoglobin A constitutes the majority of hemoglobin. However, in disorders like beta-thalassemia, there is a reduced production of beta globin chains, leading to a lower percentage of Hemoglobin A. Similarly, in sickle cell disease, a mutation in the beta globin gene results in abnormal hemoglobin, known as Hemoglobin S, reducing the proportion of Hemoglobin A. The accurate quantification of Hemoglobin A through this panel is instrumental in differentiating between various hemoglobinopathies and thalassemia syndromes, thereby guiding appropriate treatment strategies.

Part of Blood Health

Hemoglobin F, an integral component analyzed in the Thalassemia and Hemoglobinopathy Comprehensive (COMP) panel, holds significant diagnostic value in the field of hematology. This panel is extensively utilized to detect and manage various blood disorders, specifically thalassemia and hemoglobinopathies, which involve abnormal hemoglobin production or structure. Hemoglobin F, or fetal hemoglobin, normally present in high levels in fetuses and newborns, is comprised of two alpha and two gamma globin chains. Its proportion in adult blood is typically low but can be elevated in certain hematological conditions. The Thalassemia and Hemoglobinopathy COMP panel assesses the percentage of Hemoglobin F in the blood, which is crucial for diagnosing disorders like beta-thalassemia or Delta-Beta thalassemia. In these conditions, there is a disruption in beta-chain production, leading to a compensatory increase in gamma chains, thus elevating Hemoglobin F levels. Additionally, Hemoglobin F levels are also analyzed to diagnose and manage sickle cell disease, where increased Hemoglobin F can ameliorate disease symptoms. Precise measurement of Hemoglobin F through this panel aids in differentiating between various types of thalassemia and hemoglobinopathies, guiding clinicians in devising effective treatment and management strategies. The inclusion of Hemoglobin F in this comprehensive panel highlights the advancements in medical diagnostics, emphasizing its crucial role in enhancing patient care through the early detection and efficient management of genetic blood disorders.

Antigen Made From: Packaged Hemp protein powder Associated With: - Allergy Known Cross-Reactions: Triiodothyronine (T3) Clinical Significance: The presence of antibodies to Hemp is an indication of food immune reactivity. The offending food and its known cross-reactive foods should be eliminated from the diet. Hemp is emerging as a popular alternative food source, especially for vegetarians. Very few studies have been done on Hemp as a food source, although some cases of sensitization and allergy to the plant have been reported. References: 1. Popa et al. An investigation of allergy in byssinosis: sensitization to cotton, hemp, flax and jute antigens. Brit J Industr Med, 1969; 26:101-108. 2. Stokes et al. Cannabis (hemp) positive skin tests and respiratory symptoms. Ann Allergy Asthma Immunol, 2000; 85:238-240. 3. Tang et al. Enzymatic hydrolysis of hemp (Cannabis sativa L.) protein isolate by various proteases and antioxidant properties of the resulting hydrolysates. Food Chem, 2009; 114(4):1484-1490. 4. Kharrazian, et al. Immunological reactivity using monoclonal and polyclonal antibodies of autoimmune thyroid target sites with dietary proteins. J Thyroid Res, 2017; 2017:4354723.